系统综述揭示前列腺导管内癌患病率与前列腺癌风险分层的关联
该系统综述通过检索OVID Medline、PubMed和Scopus数据库,纳入24篇文章中的38个患者队列、超过7000例根治性前列腺切除和前列腺穿刺标本,分析前列腺导管内癌(IDC-P)患病率与前列腺癌风险分层的关联。结果显示IDC-P患病率从低危队列的2.1%升至中危23.1%、高危36.7%、转移或复发56.0%(p<0.0001),提示IDC-P与侵袭性前列腺癌强相关。
要点
- IDC-P患病率随风险分层升高:低危2.1%、中危23.1%、高危36.7%、转移或复发56.0%(p<0.0001)。
- 雄激素剥夺治疗或化疗后的肿瘤中IDC-P患病率高达60%。
- 提高对IDC-P的识别和系统报告可能改善患者风险分层。
核心结论
- IDC-P患病率与前列腺癌侵袭性呈强关联,高危疾病中频率显著更高,提高对IDC-P的识别和系统报告可能改善患者风险分层。
研究设计与样本
- 系统综述,检索OVID Medline、PubMed和Scopus数据库,纳入24篇文章中的38个患者队列,标本包括根治性前列腺切除和前列腺穿刺标本,来自超过7000例患者。
主要发现
- IDC-P患病率从低危患者队列的2.1%升至中危23.1%、高危36.7%、转移或复发风险类别56.0%(p<0.0001)。
- 雄激素剥夺治疗或化疗后的肿瘤中IDC-P患病率高达60%。
临床怎么用
- 作者认为,提高对IDC-P的识别和系统报告可能改善患者风险分层。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Intraductal carcinoma of the prostate (IDC-P) is associated with poor prognosis. While it is often regarded as a rare pathology, the prevalence of IDC-P remains unclear, with variable reports from small and disparate patient populations. To determine how common IDC-P is across the spectrum of prostate cancer, we conducted a systematic review correlating IDC-P prevalence with prostate cancer risk. Electronic searches of the OVID Medline, PubMed, and Scopus literature databases identified 38 patient cohorts in 24 articles, which were divided between four prostate cancer risk categories (low, moderate, high, and recurrent or metastatic disease). This review, which included radical prostatectomy and prostate biopsy specimens from >7000 patients, revealed an unexpectedly high rate of IDC-P. The IDC-P prevalence increased from 2.1% in low-risk patient cohorts to 23.1%, 36.7%, and 56.0% in moderate-risk, high-risk, and metastatic or recurrent disease risk categories, respectively (p<0.0001). IDC-P was also highly prevalent in tumours following androgen deprivation therapy or chemotherapy (60%). Contrary to common perceptions, this study demonstrates a strong association between IDC-P prevalence and aggressive prostate cancer, with a significantly higher frequency in high-risk disease. Greater recognition and systematic reporting of IDC-P may improve patient risk stratification. PATIENT SUMMARY: Prostate cancer can grow within ducts of the prostate, as well as in prostate tissue. By reviewing all reports describing prostate cancer growing within ducts, we found that it occurs more commonly than many scientists and clinicians appreciate, especially in aggressive prostate cancers. We conclude that there should be more awareness of this pattern of prostate cancer.
引用
- Porter LH, Lawrence MG, Ilic D, et al. Systematic Review Links the Prevalence of Intraductal Carcinoma of the Prostate to Prostate Cancer Risk Categories. Eur Urol. 2017. PMID: 28342640. doi:10.1016/j.eururo.2017.03.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。